glp-1 agonist dpp 4 inhibitor Glucagon-like peptide-1 Clinical Use of DPP-4 Inhibitors

L., Young, A

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease

34 There are currently 3 SGLT-2 inhibitors available in the U.S.: canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance)

34 The total MASLD activity score was calculated by summing the scores for steatosis, lobular inflammation and hepatocellular ballooning, with a possible range from 0 to 8, using deep learning applications developed by Gubra, utilising the Visiopharm software 2022.09 (Visiopharm, Denmark)

The increase of serum ANP was significantly larger in patients with eGFR 60 ml/min/1.73 m 2 23 [95%CI (17.2)(61.6)] and 9.9 [95%CI (3.8)(34.2)] respectively, p = 0.012)

In practical terms, that means the typical individual in Mississippi would need to spend roughly one-eighth of their annual income to maintain continuous GLP-1 treatment, a cost so steep it would likely require cutting back on essentials or major lifestyle expenses just to afford it